Lipoxygenase: an emerging target for stroke therapy

CNS Neurol Disord Drug Targets. 2013 Mar;12(2):191-9. doi: 10.2174/18715273112119990053.

Abstract

Neuroprotection as approach to stroke therapy has recently seen a revival of sorts, fueled in part by the continuing necessity to improve acute stroke care, and in part by the identification of novel drug targets. 12/15- Lipoxygenase (12/15-LOX), one of the key enzymes of the arachidonic acid cascade, contributes to both neuronal cell death and vascular injury. Inhibition of 12/15-LOX may thus provide multifactorial protection against ischemic injury. Targeting 12/15-LOX and related eicosanoid pathways is the subject of this brief review.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Arachidonic Acid / metabolism
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Lipoxygenase / metabolism*
  • Models, Biological
  • Stroke / drug therapy*
  • Stroke / enzymology*
  • Stroke / pathology

Substances

  • Enzyme Inhibitors
  • Arachidonic Acid
  • Lipoxygenase